优特克单抗治疗克罗恩病：它能找到自己的用武之地吗？
Ustekinumab for the treatment of Crohn's disease: can it find its niche?
作者信息
Simon Ebby G, Ghosh Subrata, Iacucci Marietta, Moran Gordon W
机构信息
Department of Gastroenterology, Christian Medical College, Vellore, India NIHR Biomedical Research Unit in Gastrointestinal and Liver Diseases, Nottingham University Hospitals NHS Trust and The University of Nottingham, Nottingham, UK.
Department of Medicine and IBD Clinic, University of Calgary, Calgary, Alberta, Canada.
出版信息
Therap Adv Gastroenterol. 2016 Jan;9(1):26-36. doi: 10.1177/1756283X15618130.
Crohn's disease is an immune-mediated disease that results in panenteric chronic inflammation in genetically predisposed individuals exposed to an appropriate environment. The past two decades have witnessed the emergence of an important class of drugs known as anti-tumour necrosis factor (TNF) agents in the treatment of Crohn's disease. Unfortunately, the utility of these agents have been hampered by primary and secondary nonresponse in a significant proportion of patients. Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin (IL) 12 and 23, is a novel pharmacotherapy for this patient cohort that offers an out-of-class option. It is approved for use in psoriasis and psoriatic arthritis, and has now been evaluated in phase II trials for moderate-to-severe Crohn's disease. We here review the published literature and describe a potential clinical role for its use in this disease cohort.
克罗恩病是一种免疫介导性疾病，在具有遗传易感性且暴露于适当环境的个体中导致全肠道慢性炎症。在过去二十年中，一类重要的药物，即抗肿瘤坏死因子（TNF）制剂，已出现用于治疗克罗恩病。不幸的是，这些制剂的效用在相当一部分患者中受到原发性和继发性无反应的阻碍。乌司奴单抗是一种针对白细胞介素（IL）12和23的p40亚基的单克隆抗体，是针对这一患者群体的一种新型药物疗法，提供了一种不同类别的选择。它已被批准用于治疗银屑病和银屑病关节炎，目前已在中重度克罗恩病的II期试验中进行了评估。我们在此回顾已发表的文献，并描述其在这一疾病群体中使用的潜在临床作用。
Zotero 插件